权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeted Protein Degradation

靶向蛋白质降解

基本信息

批准号：
10540261
负责人：
TERRY L. SHEPPARD
金额：
$ 2.01万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-12-01 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10540261
关键词：
Academia Address Autophagocytosis Biophysics Cell physiology Cells Cellular biology Chemistry Clinical Clinical Trials Collaborations Colorado Complex Cullin Proteins Degradation Pathway Development Discipline Educational workshop Endoplasmic Reticulum Degradation Pathway Fostering Future Gender Genetic Geography Heat-Shock Response Institution Knowledge Learning Ligase Methodology Modality Modeling Molecular Chaperones Outcome Participant Pharmaceutical Preparations Post-Translational Protein Processing Proteins Research Research Personnel Science Scientist Structure Students Thinking Ubiquitination career clinical practice drug discovery experience forging frontier improved insight interest multidisciplinary next generation non-Native novel novel therapeutics posters programs protein degradation protein protein interaction receptor skills small molecule symposium therapeutic target

项目摘要

ABSTRACT Support is requested for a Keystone Symposia conference entitled Targeted Protein Degradation, organized by Drs. James Bradner, Eric Fischer and Brenda Schulman. The conference will be held in Keystone, Colorado from January 29- February 1, 2023. This Keystone Symposia conference will focus on advances in the rapidly evolving field of targeted protein degradation (TPD). Over the past five years, the field has moved from proof of concept to the development of degrader drugs in clinical trials. Clinical impact has brought a sense of urgency and broadened interest for formulating and clarifying a new science of degradation. TPD has focused on cullin ring ligases and their substrate receptors, cereblon and VHL, along with other degradation pathways such as autophagy, ERAD, heat shock chaperones and monovalent degraders that are emerging as part of the TPD field. Currently small molecule degraders induce the formation of non-native protein-protein interactions. Elucidation of mechanistic details that drive ternary complex formation, and the timely sharing of these discoveries, are critical to give the field momentum and drive it forward. This Keystone Symposia conference will invite leaders in the field, from around the world, to share insights across diverse disciplines that will provide insight into the biophysics, chemistry, cell biology and genetic basis for this new science. There will a strong emphasis on renewing the spirit of face-to-face exchanges among subject matter experts with the idea to maximize interactions, formulate questions and foster new collaborations.

摘要要求支持由以下组织的题为“目标蛋白质降解”的Keystone专题讨论会会议： Drs.詹姆斯布拉德纳，埃里克菲舍尔和布伦达舒尔曼。会议将在科罗拉多的基斯通举行 2023年1月29日至2月1日。本次Keystone研讨会将重点关注快速发展的靶向蛋白领域的进展降解（TPD）。在过去的五年里，该领域已经从概念验证转向了临床试验中的降解药物。临床影响带来了紧迫感并扩大了人们的兴趣形成并阐明了一种新的降解科学。TPD专注于cullin环连接酶及其底物受体cereblon和VHL，沿着其他降解途径如自噬，ERAD，热休克分子伴侣和单价降解剂，作为TPD领域的一部分出现。目前小分子降解剂诱导非天然蛋白质-蛋白质相互作用的形成。机理解析驱动三元复合物形成的细节，以及及时分享这些发现，对于提供并推动它前进。本次Keystone研讨会将邀请该领域的领导者，在世界各地，分享不同学科的见解，这将提供对生物物理学的见解，化学、细胞生物学和遗传学基础。将大力强调更新本着主题专家之间面对面交流的精神，提出问题并促进新的合作。